GlassScriptPhysician profile
Shamil J Morayati
NPI 1083631832
$7,548.99
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,242 · 2020: $1,337 · 2021: $1,794 · 2022: $979 · 2023: $1,361 · 2024: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,118.46 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $977.32 | 2019-2024 | Korlym |
| Lilly USA, LLC | $704.35 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Abbvie INC. | $701.06 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $478.11 | 2019-2023 | |
| Amgen INC. | $459.12 | 2019-2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $327.56 | 2019-2023 | Steglatro, Belsomra |
| Amarin Pharma, INC. | $273.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.00 | 2019-2022 | |
| Ibsa Pharma INC. | $198.80 | 2019-2022 | |
| Abbott Laboratories | $192.10 | 2021-2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $172.98 | 2019-2021 | |
| Esperion Therapeutics, INC. | $171.84 | 2020-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $147.41 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $138.03 | 2021-2023 | Gvoke Hypopen |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamil Morayati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.